

Webcast Alert: Isis Pharmaceuticals, Inc. to Discuss Its 2002 First Quarter Financial Results on the Web; Live and Archived Conference Call Notification

April 23, 2002

CARLSBAD, Calif., April 23 /PRNewswire-FirstCall/ -- In conjunction with Isis Pharmaceuticals, Inc.'s (Nasdaq: ISIS) 2002 first quarter financial results discussion, you are invited to listen to its conference call that will be broadcast live over the Internet on Wednesday, April 24, at 09:00 am Eastern Daylight Time.

What: Isis Pharmaceuticals, Inc. 2002 First Quarter Financial Results

When: Wednesday, April 24, 2002 @ 09:00 am Eastern Daylight Time

Where: <http://www.videonewswire.com/event.asp?id=4330>

How: Live over the Internet -- Simply log on to the web at the address above.

Contact: Karen Lundstedt, +1-760-603-3880

Isis Pharmaceuticals, Inc. is exploiting its expertise in RNA to discover and develop novel human therapeutic drugs. The Company has commercialized its first product, Vitravene® (fomivirsen), to treat CMV-induced retinitis in AIDS patients. In addition, Isis has 13 products in its development pipeline, with two in late-stage development and six in Phase II human clinical trials. LY900003 (ISIS 3521), an inhibitor of PKC-alpha, is in Phase III trials for non-small cell lung cancer, and alicaforsen (ISIS 2302), an ICAM-1 inhibitor, is in Phase III human clinical trials for Crohn's disease. Isis has a broad patent estate, as the owner or exclusive licensee of more than 900 issued patents worldwide. Isis' GeneTrove™ division uses antisense to assist pharmaceutical industry partners in validating and prioritizing potential gene targets through customized services. Ibis Therapeutics™ is a division focused on the discovery of small molecule drugs that bind to RNA. Additional information about Isis is available at www.isispharm.com.

(Minimum Requirements to listen to broadcast: The Windows Media Player software, downloadable free from <http://www.microsoft.com/windows/windowsmedia/EN/default.asp>, and at least a 28.8Kbps connection to the Internet. If you experience problems listening to the broadcast, send an email to isproducers@prnewswire.com.)

Tell Us What You Think -- [Click Here](#)

<http://tbutton.prnewswire.com/prn/11690X72554822>

SOURCE Isis Pharmaceuticals, Inc.

Web site: <http://www.isispharm.com>

CONTACT: Karen Lundstedt of Isis Pharmaceuticals, Inc., +1-760-603-3880

Audio: <http://www.videonewswire.com/event.asp?id=4330>